Table 1.
Patient demographics and disease characteristics at diagnosis by PIK3/AKT classifications.
| Frequency (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| PIK3‐⍺ | PIK3‐β | PIK3‐δ | PIK3‐ | ||||||
| Total | Low | High | Negative | Positive | Low | High | Negative | Positive | |
| Characteristics | N = 88 | n = 74 | n = 14 | n = 9 | n = 79 | n = 30 | n = 58 | n = 38 | n = 50 |
| Age | |||||||||
| Median | 61 | 61 | 56 | 61 | 61 | 56 | 61 | 63 | 55 |
| IQR | 47·3, 71·1 | 47·3, 71·1 | 48·7, 70·3 | 54·7, 71·9 | 47·3, 70·9 | 43·2, 71·3 | 48·5, 69·5 | 54·0, 71·9 | 41·4, 70·1 |
| Range | 13·8–83·3 | 13·8–83·3 | 32·9–81·5 | 25·7–81·9 | 13·8–83·3 | 24·8–81·5 | 13·8–83·3 | 21·3–83·0 | 13·8–83·3 |
| P = 1·0* | P = 0·7* | P = 0·7* | P = 0·046* | ||||||
| Age group | |||||||||
| <60 | 41 (47·1) | 33 (45·2) | 8 (57·1) | 3 (33·3) | 38 (48·7) | 16 (53·3) | 25 (43·9) | 14 (36·8) | 27 (55·1) |
| ≥60 | 46 (52·9) | 40 (54·8) | 6 (42·9) | 6 (66·7) | 40 (51·3) | 14 (46·7) | 32 (56·1) | 24 (63·2) | 22 (44·9) |
| P = 0·4** | P = 0·5 | P = 0·4** | P = 0·09** | ||||||
| Gender | |||||||||
| Female | 26 (29·6) | 20 (27·0) | 6 (42·9) | 2 (22·2) | 24 (30·4) | 10 (33·3) | 16 (27·6) | 9 (23·7) | 17 (34·0) |
| Male | 62 (70·5) | 54 (73·0) | 8 (57·1) | 7 (77·8) | 55 (69·6) | 20 (66·7) | 42 (72·4) | 29 (76·3) | 33 (66·0) |
| P = 0·3 | P = 1·0 | P = 0·6** | P = 0·3** | ||||||
| IPI score | |||||||||
| Low (0–2) | 35 (39·8) | 30 (40·5) | 5 (35·7) | 4 (44·4) | 31 (39·2) | 11 (36·7) | 24 (41·4) | 14 (36·8) | 21 (42·0) |
| High (3–5) | 35 (39·8) | 30 (40·5) | 5 (35·7) | 3 (33·3) | 32 (40·5) | 11 (36·7) | 24 (41·4) | 20 (52·6) | 15 (30·0) |
| Not evaluated | 18 (20·5) | 14 (18·9) | 4 (28·6) | 2 (22·2) | 16 (20·3) | 8 (26·7) | 10 (17·2) | 4 (10·5) | 14 (28·0) |
| P = 0·7 (P = 1·0**) | P = 1·0 (P = 1·0) | P = 0·6** (P = 1·0**) | P = 0·05** (P = 0·2**) | ||||||
| ECOG | |||||||||
| 0–1 | 60 (68·2) | 53 (71·6) | 7 (50·0) | 7 (77·8) | 53 (67·1) | 16 (53·3) | 44 (75·9) | 28 (73·7) | 32 (64·0) |
| 2–4 | 11 (12·5) | 9 (12·2) | 2 (14·3) | 0 (0·0) | 11 (13·9) | 5 (16·7) | 6 (10·3) | 6 (15·8) | 5 (10·0) |
| Unknown | 17 (19·3) | 12 (16·2) | 5 (35·7) | 2 (22·2) | 15 (19·0) | 9 (30·0) | 8 (13·8) | 4 (10·5) | 13 (26·0) |
| P = 0·2 (P = 0·6) | P = 0·7 (P = 0·6) | P = 0·1 (P = 0·3) | P = 0·2 (P = 0·6**) | ||||||
| Stage | |||||||||
| I–II | 30 (34·1) | 25 (33·8) | 5 (35·7) | 4 (44·4) | 26 (32·9) | 12 (40·0) | 18 (31·0) | 9 (23·7) | 21 (42·0) |
| III–IV | 58 (65·9) | 49 (66·2) | 9 (64·3) | 5 (55·6) | 53 (67·1) | 18 (60·0) | 40 (69·0) | 29 (76·3) | 29 (58·0) |
| P = 1·0 | P = 0·5 | P = 0·4** | P = 0·07** | ||||||
| Elevated LDH | |||||||||
| No | 14 (15·9) | 11 (14·9) | 3 (21·4) | 1 (11·1) | 13 (16·5) | 4 (13·3) | 10 (17·2) | 7 (18·4) | 7 (14·0) |
| Yes | 67 (76·1) | 57 (77·0) | 10 (71·4) | 7 (77·8) | 60 (76·0) | 23 (76·7) | 44 (75·9) | 29 (76·3) | 38 (76·0) |
| Unknown | 7 (8·0) | 6 (8·1) | 1 (7·1) | 1 (11·1) | 6 (7·6) | 3 (10·0) | 4 (6·9) | 2 (5·3) | 5 (10·0) |
| P = 0·9 (P = 0·7) | P = 0·8 (P = 1·0) | P = 0·8 (P = 0·8) | P = 0·7 (P = 0·6**) | ||||||
| Anthracycline‐based chemo in first line | |||||||||
| No | 35 (39·8) | 29 (39·2) | 6 (42·9) | 6 (66·7) | 29 (36·7) | 12 (40·0) | 23 (39·7) | 16 (42·1) | 19 (38·0) |
| Yes | 44 (50·0) | 37 (50·0) | 7 (50·0) | 2 (22·2) | 42 (53·2) | 14 (46·7) | 30 (51·7) | 19 (50·0) | 25 (50·0) |
| Unknown | 9 (10·2) | 8 (10·8) | 1 (7·1) | 1 (11·1) | 8 (10·1) | 4 (13·3) | 5 (8·6) | 3 (7·9) | 6 (12·0) |
| P = 1·0 (P = 0·9**) | P = 0·2 (P = 0·1) | P = 0·8 (P = 0·8**) | P = 0·9 (P = 0·8**) | ||||||
| Disease type | |||||||||
| AITL | 34 (38·6) | 33 (44·6) | 1 (7·1) | 3 (33·3) | 31 (39·2) | 4 (13·3) | 30 (51·7) | 26 (68·4) | 8 (16·0) |
| NKTCL | 19 (21·6) | 13 (17·6) | 6 (42·9) | 4 (44·4) | 15 (19·0) | 12 (40·0) | 7 (12·1) | 3 (7·9) | 16 (32·0) |
| ALCL, ALK+ve | 5 (5·7) | 5 (6·8) | 0 (0·0) | 0 (0·0) | 5 (6·3) | 2 (6·7) | 3 (5·2) | 0 (0·0) | 5 (10·0) |
| ALCL, ALK−ve | 4 (4·6) | 4 (5·4) | 0 (0·0) | 0 (0·0) | 4 (5·1) | 1 (3·3) | 3 (5·2) | 3 (7·9) | 1 (2·0) |
| MEITL | 12 (13·6) | 10 (13·5) | 2 (14·3) | 2 (22·2) | 10 (12·7) | 6 (20·0) | 6 (10·3) | 3 (7·9) | 9 (18·0) |
| PTCL,NOS | 12 (13·6) | 7 (9·5) | 5 (35·7) | 0 (0·0) | 12 (15·2) | 5 (16·7) | 7 (12·1) | 2 (5·3) | 10 (20·0) |
| CTCL | 2 (2·3) | 2 (2·7) | 0 (0·0) | 0 (0·0) | 2 (2·5) | 0 (0·0) | 2 (3·5) | 1 (2·6) | 1 (2·0) |
| P = 0·01 | P = 0·6 | P = 0·003 | P < 0·001 | ||||||
IQR, interquartile range; IPI, International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; LCH, lactate dehydrogenase; AITL, angioimmunoblastic T‐cell lymphoma; NKTCL, natural killer/T‐cell lymphoma; ALCL, anaplastic large‐cell lymphoma; MEITL, monomorphic epitheliotropic intestinal T‐cell lymphoma; PTCL‐NOS, peripheral T‐cell lymphoma not otherwise specified; CTCL, cutaneous T‐cell lymphoma.
P value in parentheses calculated excluding the categories ‘Not evaluated’ and ‘Unknown’.
P value calculated using Fisher’s exact test unless otherwise stated.
*
P value calculated using the Mann–Whitney U test.
**
P value calculated using the chi‐squared test.